Cargando…

The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease

As therapeutic trials target early stages of Parkinson’s disease (PD), appropriate patient selection based purely on clinical criteria poses significant challenges. Members of the Critical Path for Parkinson’s Consortium formally submitted documentation to the European Medicines Agency (EMA) support...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephenson, Diane, Hill, Derek, Cedarbaum, Jesse M., Tome, Maria, Vamvakas, Spiros, Romero, Klaus, Conrado, Daniela J., Dexter, David T., Seibyl, John, Jennings, Danna, Nicholas, Timothy, Matthews, Dawn, Xie, Zhiyong, Imam, Syed, Maguire, Paul, Russell, David, Gordon, Mark Forrest, Stebbins, Glenn T., Somer, Ed, Gallagher, Jill, Roach, Arthur, Basseches, Peter, Grosset, Donald, Marek, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700608/
https://www.ncbi.nlm.nih.gov/pubmed/31306141
http://dx.doi.org/10.3233/JPD-191648
_version_ 1783444899751788544
author Stephenson, Diane
Hill, Derek
Cedarbaum, Jesse M.
Tome, Maria
Vamvakas, Spiros
Romero, Klaus
Conrado, Daniela J.
Dexter, David T.
Seibyl, John
Jennings, Danna
Nicholas, Timothy
Matthews, Dawn
Xie, Zhiyong
Imam, Syed
Maguire, Paul
Russell, David
Gordon, Mark Forrest
Stebbins, Glenn T.
Somer, Ed
Gallagher, Jill
Roach, Arthur
Basseches, Peter
Grosset, Donald
Marek, Kenneth
author_facet Stephenson, Diane
Hill, Derek
Cedarbaum, Jesse M.
Tome, Maria
Vamvakas, Spiros
Romero, Klaus
Conrado, Daniela J.
Dexter, David T.
Seibyl, John
Jennings, Danna
Nicholas, Timothy
Matthews, Dawn
Xie, Zhiyong
Imam, Syed
Maguire, Paul
Russell, David
Gordon, Mark Forrest
Stebbins, Glenn T.
Somer, Ed
Gallagher, Jill
Roach, Arthur
Basseches, Peter
Grosset, Donald
Marek, Kenneth
author_sort Stephenson, Diane
collection PubMed
description As therapeutic trials target early stages of Parkinson’s disease (PD), appropriate patient selection based purely on clinical criteria poses significant challenges. Members of the Critical Path for Parkinson’s Consortium formally submitted documentation to the European Medicines Agency (EMA) supporting the use of Dopamine Transporter (DAT) neuroimaging in early PD. Regulatory documents included a comprehensive literature review, a proposed analysis plan of both observational and clinical trial data, and an assessment of biomarker reproducibility and reliability. The research plan included longitudinal analysis of the Parkinson Research Examination of CEP-1347 Trial (PRECEPT) and the Parkinson’s Progression Markers Initiative (PPMI) study to estimate the degree of enrichment achieved and impact on future trials in subjects with early motor PD. The presence of reduced striatal DAT binding based on visual reads of single photon emission tomography (SPECT) scans in early motor PD subjects was an independent predictor of faster decline in UPDRS Parts II and III as compared to subjects with scans without evidence of dopaminergic deficit (SWEDD) over 24 months. The EMA issued in 2018 a full Qualification Opinion for the use of DAT as an enrichment biomarker in PD trials targeting subjects with early motor symptoms. Exclusion of SWEDD subjects in future clinical trials targeting early motor PD subjects aims to enrich clinical trial populations with idiopathic PD patients, improve statistical power, and exclude subjects who are unlikely to progress clinically from being exposed to novel test therapeutics.
format Online
Article
Text
id pubmed-6700608
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-67006082019-09-03 The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease Stephenson, Diane Hill, Derek Cedarbaum, Jesse M. Tome, Maria Vamvakas, Spiros Romero, Klaus Conrado, Daniela J. Dexter, David T. Seibyl, John Jennings, Danna Nicholas, Timothy Matthews, Dawn Xie, Zhiyong Imam, Syed Maguire, Paul Russell, David Gordon, Mark Forrest Stebbins, Glenn T. Somer, Ed Gallagher, Jill Roach, Arthur Basseches, Peter Grosset, Donald Marek, Kenneth J Parkinsons Dis Review As therapeutic trials target early stages of Parkinson’s disease (PD), appropriate patient selection based purely on clinical criteria poses significant challenges. Members of the Critical Path for Parkinson’s Consortium formally submitted documentation to the European Medicines Agency (EMA) supporting the use of Dopamine Transporter (DAT) neuroimaging in early PD. Regulatory documents included a comprehensive literature review, a proposed analysis plan of both observational and clinical trial data, and an assessment of biomarker reproducibility and reliability. The research plan included longitudinal analysis of the Parkinson Research Examination of CEP-1347 Trial (PRECEPT) and the Parkinson’s Progression Markers Initiative (PPMI) study to estimate the degree of enrichment achieved and impact on future trials in subjects with early motor PD. The presence of reduced striatal DAT binding based on visual reads of single photon emission tomography (SPECT) scans in early motor PD subjects was an independent predictor of faster decline in UPDRS Parts II and III as compared to subjects with scans without evidence of dopaminergic deficit (SWEDD) over 24 months. The EMA issued in 2018 a full Qualification Opinion for the use of DAT as an enrichment biomarker in PD trials targeting subjects with early motor symptoms. Exclusion of SWEDD subjects in future clinical trials targeting early motor PD subjects aims to enrich clinical trial populations with idiopathic PD patients, improve statistical power, and exclude subjects who are unlikely to progress clinically from being exposed to novel test therapeutics. IOS Press 2019-07-30 /pmc/articles/PMC6700608/ /pubmed/31306141 http://dx.doi.org/10.3233/JPD-191648 Text en © 2019 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Stephenson, Diane
Hill, Derek
Cedarbaum, Jesse M.
Tome, Maria
Vamvakas, Spiros
Romero, Klaus
Conrado, Daniela J.
Dexter, David T.
Seibyl, John
Jennings, Danna
Nicholas, Timothy
Matthews, Dawn
Xie, Zhiyong
Imam, Syed
Maguire, Paul
Russell, David
Gordon, Mark Forrest
Stebbins, Glenn T.
Somer, Ed
Gallagher, Jill
Roach, Arthur
Basseches, Peter
Grosset, Donald
Marek, Kenneth
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
title The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
title_full The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
title_fullStr The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
title_full_unstemmed The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
title_short The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
title_sort qualification of an enrichment biomarker for clinical trials targeting early stages of parkinson’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700608/
https://www.ncbi.nlm.nih.gov/pubmed/31306141
http://dx.doi.org/10.3233/JPD-191648
work_keys_str_mv AT stephensondiane thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT hillderek thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT cedarbaumjessem thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT tomemaria thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT vamvakasspiros thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT romeroklaus thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT conradodanielaj thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT dexterdavidt thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT seibyljohn thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT jenningsdanna thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT nicholastimothy thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT matthewsdawn thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT xiezhiyong thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT imamsyed thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT maguirepaul thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT russelldavid thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT gordonmarkforrest thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT stebbinsglennt thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT somered thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT gallagherjill thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT roacharthur thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT bassechespeter thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT grossetdonald thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT marekkenneth thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT thequalificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT stephensondiane qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT hillderek qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT cedarbaumjessem qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT tomemaria qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT vamvakasspiros qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT romeroklaus qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT conradodanielaj qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT dexterdavidt qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT seibyljohn qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT jenningsdanna qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT nicholastimothy qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT matthewsdawn qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT xiezhiyong qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT imamsyed qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT maguirepaul qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT russelldavid qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT gordonmarkforrest qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT stebbinsglennt qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT somered qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT gallagherjill qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT roacharthur qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT bassechespeter qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT grossetdonald qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT marekkenneth qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease
AT qualificationofanenrichmentbiomarkerforclinicaltrialstargetingearlystagesofparkinsonsdisease